Methotrexate and emerging therapies

More publications in the medical literature have described the clinical eff icacy and toxicity of methotrexate (MTX) than of any other drug ever used f or rheumatic diseases. A knowledgeable clinican can thus rely on evidence-b ased medicine to guide the use of this agent. Because MTX is not remission- inducing, many new therapies are being combined with it in order to achieve a greater therapeutic response. This trend will likely continue and expand as more novel agents are introduced.